A Pilot Study for Return of Individual Pharmacogenomic Results to Population-Based Cohort Study Participants.

ABSTRACT:

Introduction

Pharmacogenomic (PGx) testing results provide valuable information on drug selection and appropriate dosing, maximization of efficacy, and minimization of adverse effects. Although the number of large-scale, next-generation-sequencing-based PGx studies has recently increased, little is known about the risks and benefits of returning PGx results to ostensibly healthy individuals in research settings.

Methods

Single-nucleotide variants of three actionable PGx genes, namely, MT-RNR1, CYP2C19, and NUDT15, were returned to 161 participants in a population-based Tohoku Medical Megabank project. Informed consent was obtained from the participants after a seminar on the outline of this study. The results were sent by mail alongside sealed informatio

SUBMITTER: Ohneda K 

PROVIDER: S-EPMC9090545 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature